Director, Cell Therapy Manufacturing Facility
MedStar Georgetown University Hospital
WASHINGTON, District of Columbia, United States
Dr. Wanxing Cui leads the Cell Therapy Manufacturing Facility at MedStar Georgetown University Hospital, blending a diverse background in academia, industry, and healthcare in the realm of cell therapy. His medical odyssey began in Shenyang, China, transitioning from a surgical residency to earning a Ph.D. from Kyoto University, where he focused on bioartificial pancreas development.
As director of an FDA-registered facility accredited by both the Association for the Advancement of Blood & Biotherapies (AABB) and the Foundation for the Accreditation of Cellular Therapy (FACT), Dr. Cui plays a crucial role in the Pancreatic Islets and Hematopoietic Progenitor Cells Transplantation programs at his institution. His distinguished career in pancreatic islet transplantation spans over 27 years, marked by more than 70 peer-reviewed publications and several biotechnological patents.
Within AABB, Dr. Cui is actively involved in the Cellular Therapies Section Coordinating Committee, contributing to the advancement of cell therapy standards. He also serves as an AABB assessor and a FACT inspector, upholding the highest quality practices in the field. Parallel to his work with AABB, Dr. Cui is also engaged with the International Society for Cell & Gene Therapy (ISCT). Here, he contributes to the iPSC Joint and Lab Practice Committees, offering his expertise in innovative cellular therapies. Committed to mentorship, Dr. Cui supports the professional growth of upcoming experts through his involvement in ISCT's Professional Education Program (PEP) and AABB's Early Stage Professionals (ESP) programs. His interdisciplinary expertise and impactful contributions position him as an invaluable member of the AABB CTSCC committee, driving progress in cell therapies.
Saturday, October 19, 2024
11:15 AM - 12:15 PM
Disclosure(s): No financial relationships to disclose